Floatz logo

Proxalutamide

Androgenetic Alopecia

Applied Biology, Inc.N/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Androgenetic Alopecia cohort.

Asset / SponsorPhaseRating
Finasteride
HairDx, LLC
Phase 1CC
cb-03-10
Cosmo Technologies Ltd
Early Phase 1NR

Same molecule, other indications

Proxalutamide is also rated in:

breast cancerDormant
CC
Indicative ·
42 / 100
View asset →
COVID-19Dormant
D
Indicative ·
30 / 100
View asset →
benign prostatic hyperplasiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →